Abstract
The urinary excretion of doxifluridine (5′ dFUrd) and its metabolites was determined during five days of chemotherapy using fluorine-19 nuclear magnetic resonance spectrometry. The daily urinary excretion of 5′ dFUrd and its metabolites was high (∼-100% of the 5′ dFUrd administered) and nearly constant through out the treatment. By far the major excreted compounds were unchanged 5′ dFUrd and α-fluoro-β-alanine which made up respectively ∼-40% and ∼-50% of the total. Neither accumulation of 5′ dFUrd nor significant modifications in its metabolism were observed during the treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Armstrong RD, Diasio RB: Metabolism and biological activity of 5′-deoxy-5-fluorouridine, a novel fluoropyrimidine. Cancer Res 40:3333–3339, 1980
Bollag W, Hartmann HR: Tumor inhibitory effects of a new fluorouracil derivative: 5′-deoxy-5-fluorouridine. Eur J Cancer 16:427–432, 1980
Ishitsuka H, Miwa W, Takemoto K, Fukuoka K, Itoga A, Maruyama HB: Role of uridine phosphorylase for antitumor activity of 5′-deoxy-5-fluorouridine. Gann 71: 112–123, 1980
Abele R, Alberto P, Seematter RJ, Germano G, Heintz R, Bollag W: Phase I clinical study with 5′-deoxy-5-fluorouridine, a new fluoropyrimidine derivative. Cancer Treat Rep 66:1307–1313, 1982
Abele R, Alberto P, Kaplan S, Siegenthaler P, Hofmann V, Ryssel HJ, Hartmann D, Holdener EE, Cavalli F: Phase II study of doxifluridine in advanced colorectal adenocarcinoma. J Clin Oncol 1:750–754, 1983
Abele R, Kaplan E, Grossenbacher R, Schmid HJ, Cavalli F: Phase II study of doxifluridine in advanced squamous cell carcinoma of the head and neck. Eur J Cancer Clin Oncol 20:333–336, 1984
Shimizu E, Saijo N, Eguchi K, Shinkai T, Tominaga K, Sasaki Y, Fujita J, Nomori H, Hoshi A: Phase II study of oral administration of 5′-deoxy-5-fluorouridine (5′-DFUR) for solid tumors. Jpn J Clin Oncol 14:679–684, 1984
Fossa SD, Dahl O, Hoel R, Heier M, Loeb M: Doxifluridine (5′ dFUrd) in patients with advanced colorectal carcinoma. A phase II study. Cancer Chemother Pharmacol 15: 161–163, 1985
Hurteloup P, Armand JP, Cappelaere P, Metz R, Kerbrat P, Keiling R, Fumoleau P, Fargeot P, Schraub S, Bastit P, Caudry M, Cauchie C, Nasca S, Pommatau E, Hayat M, Chollet P, Renard J, Van Glabbeke M, Mathé G: Phase II clinical evaluation of doxifluridine. Cancer Treat Rep 70: 731–737, 1986
Alberto P, Rozencweig M, Clavel M, Siegenthaler P, Cavalli F, Gundersen S, Bruntsch U, Renard J, Pinedo H: Phase II study of 5′-deoxy-5-fluorouridine (doxifluridine) in advanced malignant melanoma. Cancer Chemother Pharmacol 16:78–79, 1986
De Bruijn EA, Van Oosterom AT, Tjaden UR, Reenwijk HJEM, Pinedo HM: Pharmacology of 5′-deoxy-5-fluorouridine in patients with resistant ovarian cancer. Cancer Res 45:5931–5935, 1985
Malet-Martino MC, Armand JP, Lopez A, Bernadou J, Béteille JP, Bon M, Martino R: Evidence for the importance of 5′-deoxy-5-fluorouridine catabolism in humans from 19F nuclear magnetic resonance spectrometry. Cancer Res 46:2105–2112, 1986
Heier MS, Fossa SD: Neurological manifestations in a phase II study of 13 patients treated with doxifluridine. Acta Neurol Scand 72:171–175, 1985
Heier MS, Fossa SD: Wernicke-Korsakoff — like syndrome in patients with colorectal carcinoma treated with high-dose doxifluridine (5′-dFUrd). Acta Neurol Scand 73:449–457, 1986
Martino R, Malet-Martino MC, Vialaneix C, Lopez A, Bon M: Fluorine-19 MNR study of carbamate reaction of α-fluoro-β-alanine, the major catabolite of fluoropyrimidines. Application to α-fluoro-β-alanine carbamate determination in biofluids of patients treated with 5′-deoxy-5-fluorouridine. Submitted for publication.
Mukherjee KL, Heidelberger C: Studies on fluorinated pyrimidines. IX. The degradation of 5-fluorouracil-6-C14. J Biol Chem 235:433–437, 1960
Mukherjee KL, Boohar J, Wentland D, Ansfield FJ, Heidelberger C: Studies on fluorinated pyrimidines. XVI. Metabolism of 5-fluorouracil-2-C14 and 5-fluoro-2′-deoxyuridine-2-C14 in cancer patients. Cancer Res 23:49–66, 1963
Bernadou J, Armand JP, Lopez A, Malet-Martino MC, Martino R: Complete urinary excretion profile of 5-fluorouracil during a six-day chemotherapeutic schedule, as resolved by 19F nuclear magnetic resonance. Clin Chem31:846–848, 1985
De Bruijn EA, Van Oosterom AT, Pinedo HM, Reeuwijk HJEM, Van Der Kaay M, Tjaden UR: Pharmacokinetics of 5′-deoxy-5-fluorouridine (5′-dFUR) after intravenous administration to patients with ovarian cancer. Proceedings of the Second European Conference on Clinical Oncology, Amsterdam, 1983
Heintz RC, Güntert TW, Abele R, Alberto P, Cano JP, Germano G: Single dose pharmacokinetics of doxifluridine and of some of its metabolites following rapid intravenous injection to cancer patients. Proceedings of the Second European Conference on Clinical Oncology, Amsterdam, 1983
Sommadossi JP, Aubert C, Jacquet J, Iliadis A, Cano JP: The pharmacology and metabolism of 5′-deoxy-5-fluorouridine. Int Congr Ser Excerpta Med 647:108–120, 1984
Heintz RC, Guentert TW, Sutter-Melde C, LinderCiccolunghi SN: Pharmacokinetic profile of doxifluridine (5′ dFUR, FurtulonR), a 5-fluorouracil (5FU) pro-drug. (Abstr) Proc Am Assoc Cancer Res 27:207, 1986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Malet-Martino, M.C., Servin, P., Bernadou, J. et al. Human urinary excretion of doxifluridine and metabolites during a 5-day chemotherapeutic schedule using fluorine-19 nuclear magnetic resonance spectrometry. Invest New Drugs 5, 273–279 (1987). https://doi.org/10.1007/BF00175298
Issue Date:
DOI: https://doi.org/10.1007/BF00175298